Y-mAbs Therapeutics initiated with a Buy at H.C. Wainwright. H.C. Wainwright analyst Raghuram Selvaraju started Y-mAbs Therapeutics with a Buy rating and $36 price target. The company has a “highly differentiated business model,” focusing on rare, hitherto difficult-to-treat pediatric cancers with next-generation monoclonal antibody therapeutics, Selvaraju tells investors in a research note. He believes the company’s is a platform “possesses multiple advantages.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.